Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables - Other: 2023-2025

Historic Receivables - Other for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $203,000.

  • BioLineRx's Receivables - Other fell 69.05% to $203,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $203,000, marking a year-over-year decrease of 69.05%. This contributed to the annual value of $1.5 million for FY2024, which is 78.07% up from last year.
  • As of Q2 2025, BioLineRx's Receivables - Other stood at $203,000, which was down 55.09% from $452,000 recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Receivables - Other ranged from a high of $1.5 million in Q4 2024 and a low of $128,000 during Q2 2023.
  • Its 3-year average for Receivables - Other is $522,100, with a median of $401,000 in 2024.
  • In the last 5 years, BioLineRx's Receivables - Other skyrocketed by 412.50% in 2024 and then slumped by 69.05% in 2025.
  • Quarterly analysis of 3 years shows BioLineRx's Receivables - Other stood at $830,000 in 2023, then skyrocketed by 78.07% to $1.5 million in 2024, then slumped by 69.05% to $203,000 in 2025.
  • Its Receivables - Other stands at $203,000 for Q2 2025, versus $452,000 for Q1 2025 and $1.5 million for Q4 2024.